James Madison
Member
- Joined
- Feb 11, 2008
- Messages
- 5,121
Ronald Bailey|Nov. 25, 2013 12:42 pm
For a couple of years, I have been warning all my friends and colleagues to purchase $99 personal genome testing from 23andMe before the Feds banned it. Well, now the Food and Drug Administration has banned it sending the genome testing company a warning letter:
What the test results would actually lead patients to do is to get another test and to talk with their physicians. The FDA also cites the genotype results that indicate the sensitivity of patients to the blood-thinning medication warfarin. Again, such results would be used by patients to talk with their doctors about their treatment regimens should the time come that they need to take the drug. In fact, in 2010 the FDA actually updated its rules to recommend genetic testing to set the proper warfarin dosages for patients.
It is notable that the FDA cites not one example of a patient being harmed through the use of 23andMe's genotype screening test. Nevertheless the agency orders that...
The FDA bureaucrats think that they know better than you how to handle your genetic information. This is outrageous.
For more background, see my 2011 Reason article on my own genetic testing experience here and go to SNPedia here for even more information on my genetic flaws.
H/T Mike Riggs and Andrew Mayne.
http://reason.com/blog/2013/11/25/fda-shuts-down-23andme-outrageously-bann
This is relevant:
http://www.lewrockwell.com/lrc-blog/inside-the-incredibly-repellent-mind-of-a-bureaucrat/
For a couple of years, I have been warning all my friends and colleagues to purchase $99 personal genome testing from 23andMe before the Feds banned it. Well, now the Food and Drug Administration has banned it sending the genome testing company a warning letter:
The Food and Drug Administration (FDA) is sending you this letter because you are marketing the 23andMe Saliva Collection Kit and Personal Genome Service (PGS) without marketing clearance or approval in violation of the Federal Food, Drug and Cosmetic Act (the FD&C Act).
This product is a device within the meaning of section 201(h) of the FD&C Act, 21 U.S.C. 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body. For example, your company’s website at www.23andme.com/health (most recently viewed on November 6, 2013) markets the PGS for providing “health reports on 254 diseases and conditions,” including categories such as “carrier status,” “health risks,” and “drug response,” and specifically as a “first step in prevention” that enables users to “take steps toward mitigating serious diseases” such as diabetes, coronary heart disease, and breast cancer. Most of the intended uses for PGS listed on your website, a list that has grown over time, are medical device uses under section 201(h) of the FD&C Act. Most of these uses have not been classified and thus require premarket approval or de novo classification, as FDA has explained to you on numerous occasions.
The FDA says it is concerned that consumers would misunderstand genetic marker information and self treat. For example, the agency cites the company for testing for versions of the BRCA gene that confers higher risk of breast cancer worrying that women might get a false positive test leading "a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions....
What the test results would actually lead patients to do is to get another test and to talk with their physicians. The FDA also cites the genotype results that indicate the sensitivity of patients to the blood-thinning medication warfarin. Again, such results would be used by patients to talk with their doctors about their treatment regimens should the time come that they need to take the drug. In fact, in 2010 the FDA actually updated its rules to recommend genetic testing to set the proper warfarin dosages for patients.
It is notable that the FDA cites not one example of a patient being harmed through the use of 23andMe's genotype screening test. Nevertheless the agency orders that...
...23andMe must immediately discontinue marketing the PGS (Personal Genome Service) until such time as it receives FDA marketing authorization for the device.
The FDA bureaucrats think that they know better than you how to handle your genetic information. This is outrageous.
For more background, see my 2011 Reason article on my own genetic testing experience here and go to SNPedia here for even more information on my genetic flaws.
H/T Mike Riggs and Andrew Mayne.
http://reason.com/blog/2013/11/25/fda-shuts-down-23andme-outrageously-bann
This is relevant:
…Marthe Kent, OSHA’s director of safety standards program and head of the ergonomics effort, couldn’t be happier at her job. ‘I like having a very direct and very powerful impact on worker safety and health,’ she recently told The Synergist, a newsletter of the American Industrial Hygiene Association. ‘If you put out a reg, it matters. I think that’s really where the thrill comes from. And it is a thrill; it’s a high.’ Later in the article, she adds, ‘I love it; I absolutely love it. I was born to regulate. I don’t know why, but that’s very true. So as long as I’m regulating, I’m happy.
http://www.lewrockwell.com/lrc-blog/inside-the-incredibly-repellent-mind-of-a-bureaucrat/